Recent studies have indicated that FGFR4 deficiency might regulate the tumor immune microenvironment by activating the antigen presentation process and cellular immunity to the change in sensitivity to immune checkpoint inhibitor treatment in NSCLC [26]. Here, FGFR4 is linked to neoplasm.